Oncology

GSK, iTeos Therapeutics to co-develop and co-commercialise cancer drug

GlaxoSmithKline (GSK) and iTeos Therapeutics have signed an agreement to co-develop and co-commercialise EOS-448, an anti-TIGIT monoclonal antibody presently under phase I development as a potential treatment for cancer patients.

BMS signs cancer therapy deal worth $1.5bn with Agenus

Bristol-Myers Squibb (BMS) has agreed to obtain a worldwide exclusive licence to a cancer antibody programme, AGEN1777, and a second undisclosed target developed by immuno-oncology firm Agenus.

Dr. Reddy’s signs license deal for anti-BCMA CAR-T PRG1801 in India

Dr. Reddy's Laboratories has signed an agreement with Shenzhen Pregene Biopharma to acquire an exclusive license in India for PRG1801, Pregene's single domain antibody-based anti-BCMA chimeric antigen receptor T (CAR-T) cell therapy injection.

Second indication of Sarclisa for relapsed multiple myeloma approved by EC

The second indication of Sarclisa (isatuximab) for the treatment of adult patients with relapsed multiple myeloma, was approved by the European Commission (EC).

Trodelvy granted accelerated approval by USFDA for metastatic urothelial cancer

Gilead Sciences has announced the accelerated approval of Trodelvy (or sacituzumab govitecan-hziy) by the US Food and Drug Administration (FDA) in the treatment of locally advanced or metastatic urothelial cancer (UC) in adult patients.

Sanofi acquires Tidal Therapeutics

Global biopharmaceutical company Sanofi has acquired privately owned, pre-clinical stage biotech company Tidal Therapeutics, which brings with it an mRNA-based approach for in vivo (inside the body) reprogramming of immune cells.

Anixa and OntoChem enter next stage of Covid-19 anti-viral therapy development

Biotechnology company Anixa Biosciences, partnered by IT and pharma solutions company OntoChem, has announced that it will enter the next stage of development of its potential anti-viral therapy for Covid-19.

USFDA sends CRL to Merck’s sBLA regarding KEYTRUDA

Merck has announced that the US Food and Drug Administration (FDA) has sent a Complete Response Letter (CRL) regarding Merck’s supplemental Biologics License Application (sBLA) for the approval of KEYTRUDA.

Ambrx gets orphan drug designation for gastric cancer treatment ARX788

The US Food and Drug Administration (FDA) grants orphan drug designation to Ambrx for ARX788, a homogeneous and highly stable antibody drug conjugate, for the treatment of HER2-positive gastric cancer.